Osteosarcoma of the extremities: chemotherapy experience at Memorial Sloan-Kettering.
作者： Paul A. Meyers , Glenn Heller , Vaia Vlamis
DOI: 10.1007/978-1-4615-3518-8_37
关键词:
摘要: At the Memorial Sloan-Kettering Cancer Center (MSKCC) multiagent chemotherapy for treatment of osteosarcoma (OS) was introduced by Dr. Gerald Rosen in 1973[1]. and Marcove developed concept an initial period prior to definitive surgery primary tumor (neoadjuvant chemotherapy). The impetus this strategy came from need create custom prostheses limb-sparing surgery. Huvos examined tumors removed at degree necrosis present following neoadjuvant [2]. They demonstrated a strong correlation between histologically evaluated response subsequent disease-free survival (DFS).
springer.com
sci-hub.st 参考文章(9)
Gerald Rosen, Preoperative (neoadjuvant) chemotherapy for osteogenic sarcoma: a ten year experience. Orthopedics. ,vol. 8, pp. 659- 664 ,(1985) , 10.3928/0147-7447-19850501-19
Pratt Cb, Jaffe N, Epelman S, Bleomycin, cyclophosphamide, and dactinomycin in metastatic osteosarcoma: lack of tumor regression in previously treated patients. Cancer treatment reports. ,vol. 71, pp. 421- 423 ,(1987)
K Winkler, G Beron, G Delling, U Heise, H Kabisch, C Purfürst, J Berger, J Ritter, H Jürgens, V Gerein, Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. Journal of Clinical Oncology. ,vol. 6, pp. 329- 337 ,(1988) , 10.1200/JCO.1988.6.2.329
Crisanta Mosende, Manuel Gutierrez, Brenda Caparros, Gerald Rosen, Combination chemotherapy with bleomycin, cyclophosphamide and dactinomycin for the treatment of osteogenic sarcoma. Cancer. ,vol. 40, pp. 2779- 2786 ,(1977) , 10.1002/1097-0142(197712)40:6<2779::AID-CNCR2820400604>3.0.CO;2-E
K. Winkler, S. Bielack, G. Delling, M. Salzer-Kuntschik, R. Kotz, C. Greenshaw, H. Jürgens, J. Ritter, C. Kusnierz-Glaz, R. Erttmann, G. Gädicke, N. Graf, R. Ladenstein, S. Leyvraz, R. Mertens, P. Weinel, Effect of intraarterial versus intravenous cisplatin in addition to systemic doxorubicin, high-dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (study COSS-86) Cancer. ,vol. 66, pp. 1703- 1710 ,(1990) , 10.1002/1097-0142(19901015)66:8<1703::AID-CNCR2820660809>3.0.CO;2-V
Gerald Rosen, M. Lois Murphy, Andrew G. Huvos, Manuel Gutierrez, Ralph C. Marcove, Chemotherapy,en bloc resection, and prosthetic bone replacement in the treatment of osteogenic sarcoma Cancer. ,vol. 37, pp. 1- 11 ,(1976) , 10.1002/1097-0142(197601)37:1<1::AID-CNCR2820370102>3.0.CO;2-3
Gerald Rosen, Ralph C. Marcove, Brenda Caparros, Anita Nirenberg, Cynthia Kosloff, Andrew G. Huvos, Primary osteogenic sarcoma. The rationale for preoperative chemotherapy and delayed surgery Cancer. ,vol. 43, pp. 2163- 2177 ,(1979) , 10.1002/1097-0142(197906)43:6<2163::AID-CNCR2820430602>3.0.CO;2-S
Gerald Rosen, Brenda Caparros, Andrew G. Huvos, Cynthia Kosloff, Anita Nirenberg, Adrienne Cacavio, Ralph C. Marcove, Joseph M. Lane, Bipin Mehta, Christian Urban, Preoperative chemotherapy for osteogenic sarcoma:Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy Cancer. ,vol. 49, pp. 1221- 1230 ,(1982) , 10.1002/1097-0142(19820315)49:6<1221::AID-CNCR2820490625>3.0.CO;2-E
M. Krailo, I. Ertel, J. Makley, C. J. H. Fryer, E. Baum, R. Weetman, E. Yunis, L. Barnes, W. A. Bleyer, G. Denman Hammond, A randomized study comparing high-dose methotrexate with moderate-dose methotrexate as components of adjuvant chemotherapy in childhood nonmetastatic osteosarcoma: A report from the childrens cancer study group Medical and Pediatric Oncology. ,vol. 15, pp. 69- 77 ,(1987) , 10.1002/MPO.2950150205